Loading
A phase 3 trial of 177Lu-edotreotide, Temozolomide, Capecitabine, Everolimus, Leucovorin (folinic acid) and Oxaliplatin in neuroendocrine tumours, run by ITM Solucin GmbH, active and no longer recruiting.
Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE is a phase 3 interventional study registered as NCT04919226 by ITM Solucin GmbH, with 259 participants enrolled, started 2021-12-21 and due to reach its primary completion in 2027-06. Interventions recorded: 177Lu-Edotreotide (Peptide Receptor Radionuclide Therapy) PRRT, CAPTEM (Capecitabine and Temozolomide), Everolimus and FOLFOX (Folinic acid + Fluorouracil + Oxaliplatin).
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Dosimetry-personalised PRRT instead of four fixed cycles, Grade 3 well-differentiated neuroendocrine tumour, Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours and the tag pipeline.
Shares Small intestinal neuroendocrine tumours, Pancreatic neuroendocrine tumours, Neuroendocrine tumours and the tag pipeline.
Shares Leucovorin (folinic acid), Oxaliplatin, Capecitabine and the tag pipeline.
Shares Leucovorin (folinic acid), Oxaliplatin, Capecitabine and the tag pipeline.
Shares Pancreatic neuroendocrine tumours, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Shares Oxaliplatin, Capecitabine and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/